Development, Commercialization and Supply Agreements (Tables)

3 Months Ended

Mar. 31, 2025

License And Collaboration Agreements [Line Items]


In thousands	Amount
Licensing revenue recognized during the three months ended March 31, 2025 (1)	$	—
Licensing revenue recognized during the three months ended March 31, 2024 (1)		376
Licensing revenue recognized from contract inception through both March 31, 2025 and December 31, 2024	$	40,081

(1)

Licensing revenue under the DCS Agreement is recognized concurrent with the input measure of support hours provided by Amarin to Edding in achieving the combined development and regulatory performance obligation, which in the Company’s judgment is the best measure of progress towards satisfying this performance obligation.

Summary of Product Approval

The Company received approval of VASCEPA under the MARINE and REDUCE-IT indications in the following countries:


Country	MARINE	REDUCE-IT	Launch Date
Lebanon	March 2018	August 2021	June 2018
United Arab Emirates	July 2018	October 2021	February 2019
Qatar	December 2019	April 2021	May 2022
Bahrain	April 2021	April 2022	September 2023
Kuwait	December 2021	March 2023	September 2023
Saudi Arabia	March 2022	June 2023	September 2023

Changes in Balances of Contract Assets and Liabilities and Revenues Recognized

The following table presents changes in the balances of the Company’s contract assets and liabilities during the three months ended March 31, 2025 and 2024:


In thousands	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Three months ended March 31, 2025:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	—	$	—	$	—		$	—

Three months ended March 31, 2024:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	4,850	$	—	$	(401	)	$	4,449

During the three months ended March 31, 2025 and 2024, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods:


In thousands	Three months ended March 31,
Revenue recognized in the period from:	2025		2024
Amounts included in contract liability at the beginning of the period	$	—	$	401

Edding

License And Collaboration Agreements [Line Items]

Summary of Transaction Price Comprising Upfront Payments and Milestones

The transaction price is comprised of the following upfront payments and milestones:


In thousands
Transaction Price Components	Achieved	Amount
Upfront fee	February 2015	$	15,000
Submission of the CTA for the MARINE indication	March 2016		1,000
Approval of VASCEPA under the MARINE indication	March 2017		5,000
Submission of the CTA for the REDUCE-IT indication	October 2023		3,000
Approval of VASCEPA under the REDUCE-IT indication	June 2024		15,000
Regulatory Development Support	Various		1,081
Total Transaction Price		$	40,081

HLS

License And Collaboration Agreements [Line Items]

Summary of Transaction Price Comprising Upfront Payments and Milestones

The transaction price is comprised of the following upfront payments and milestones:


In thousands
Transaction Price Components	Achieved	Amount
Upfront fee	September 2017	$	5,000
Achievement of the REDUCE-IT trial primary endpoint	September 2018		2,500
Approval from Health Canada	December 2019		2,500
Regulatory exclusivity from the Office of Patented Medicines and Liaison	January 2020		3,800
Total Transaction Price		$	13,800